GLP-1s for PCOS: What the Evidence Actually Shows

Why GLP-1s for PCOS

Why the GLP-1 Class Maps Onto PCOS

Polycystic ovary syndrome is fundamentally a disorder of androgen excess, ovulatory dysfunction, and — in most patients — insulin resistance. Insulin resistance and the resulting hyperinsulinemia drive ovarian androgen production, suppress sex hormone-binding globulin, and worsen metabolic, dermatologic, and reproductive symptoms.

Anything that reduces insulin resistance tends to improve every domain of PCOS. Metformin has been the standard pharmacologic option for decades. GLP-1 receptor agonists improve insulin sensitivity more powerfully than metformin, produce meaningful weight loss, and target the same metabolic root.

Evidence

What the Trials Show

Multiple randomized trials and meta-analyses in 2020–2025 have evaluated GLP-1 agonists (mostly liraglutide and semaglutide) in women with PCOS:

• ·Weight loss is consistently greater on GLP-1s than on metformin in head-to-head comparisons, typically by 5–10 percentage points of total body weight at 6–12 months.
• ·Insulin resistance markers (HOMA-IR) improve more on GLP-1s than metformin.
• ·Androgen levels (total testosterone, free androgen index) decrease meaningfully.
• ·Menstrual regularity improves in 40–70% of previously oligomenorrheic patients across studies.
• ·A meta-analysis of GLP-1s in PCOS published in 2023 reported substantial improvements across weight, glycemic, and reproductive endpoints.

Tirzepatide-specific PCOS trials are emerging in 2025–2026; early signals suggest the dual GIP/GLP-1 mechanism may produce even larger metabolic improvements.

Who's a candidate

Who PCOS Specialists Are Treating with GLP-1s

Strong candidates: women with PCOS plus overweight/obesity, documented insulin resistance, prediabetes or type 2 diabetes, and women who failed or did not tolerate metformin.

Reasonable candidates: women with PCOS at normal weight but with significant metabolic markers (high HOMA-IR, elevated triglycerides, low HDL).

Not candidates: women actively trying to conceive (see fertility/pregnancy guidance), women with personal or family history of medullary thyroid cancer, MEN2, or active pancreatitis.

Off-label

Off-Label Status and What That Means

As of mid-2026 no GLP-1 is FDA-approved with PCOS as a labeled indication. Prescribing for PCOS is off-label — legal and clinically appropriate when the medication is FDA-approved for a related condition (diabetes, obesity) and the patient meets criteria for that approved indication. Most PCOS patients on GLP-1s qualify on the basis of obesity or prediabetes.

Insurance coverage typically follows the FDA-approved indication, not the off-label use. Coverage is more likely under the diabetes or obesity indication than under PCOS.

Practical

What Treatment Looks Like in Practice

Dosing follows the standard semaglutide or tirzepatide titration schedule for obesity. Monitoring includes routine metabolic markers, menstrual cycle tracking, and androgen markers (often at 3 and 6 months).

Hair changes, acne improvement, and menstrual regularity typically appear at 3–6 months as weight and insulin resistance shift. Reproductive intent matters: if pregnancy is on the near-term horizon, the medication should be stopped per current labeling (see fertility guidance).